Skip to main content

Advertisement

SpringerLink
Log in

Renal Denervation for Resistant Hypertension: Past, Present, and Future

  • Resistant Hypertension (E Pimenta, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Renal denervation (RDN) for treatment of resistant hypertension was introduced only 5 years ago. A clear pathophysiological role of renal sympathetic activity for the initiation and maintenance of hypertension and promising data showing a substantial and sustained blood pressure (BP) reduction after RDN has promoted the widespread use of the method at least in Europe. However, in a pivotal trial that included a sham-control group, no significant BP lowering effects was observed. Afterwards, it became clear that methodological issues and poor performance and execution of the intervention have hampered the results of Symplicity HTN-3 study, thereby limiting its validity profoundly. Now, in 2015, the renaissance of RDN has begun and new randomized prospective clinical trials have or will be started soon. In the meantime, it may be wise not to ignore all previous findings, as a rescue therapy for treatment resistant hypertension. A new science era emerged, with changes of the interventional approach and selection of patients potentially profiting most from RDN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898–902.

    Article  PubMed  Google Scholar 

  2. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28:463–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–42.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr SC, Crowley K, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34:1204–14.

    Article  CAS  PubMed  Google Scholar 

  5. Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014;127:71–81 e71.

  6. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3–20.

    Article  CAS  PubMed  Google Scholar 

  7. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501–4.

    Article  CAS  PubMed  Google Scholar 

  8. Katholi RE. Renal nerves and hypertension: an update. Fed Proc. 1985;44:2846–50.

    CAS  PubMed  Google Scholar 

  9. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–197.

    CAS  PubMed  Google Scholar 

  10. Oldham JB. Denervation of the kidney. Ann R Coll Surg Engl. 1950;7:222–45.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.

    Article  PubMed  Google Scholar 

  12. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9.

    Article  Google Scholar 

  13. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622–9.

    Article  PubMed  Google Scholar 

  14. Esler MD, Bohm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35:1752–9.

    Article  PubMed  Google Scholar 

  15. Wang Q, Guo R, Rong S, Yang G, Zhu Q, Jiang Y, et al. Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. J Am Coll Cardiol. 2013;61:2185–92.

    Article  PubMed  Google Scholar 

  16. Ormiston JA, Anderson T, Brinton TJ, Dawood O, Gertner, M, Kay P, et al. Non-invasive renal denervation using externally delivered focused ultrasound: early experience using Doppler based imaging tracking and targeting for treatment. J Am Coll Cardiol. 2014;64(11_S). doi:10.1016/j.jacc.2014.07.461. Aggregate analysis of patients (Wave I–III trial), who underwent externally focussed ultrasound for renal denervation.

  17. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9.

    Article  PubMed  Google Scholar 

  18. Mahfoud F, Urban D, Teller D, Linz D, Stawowy P, Hassel JH, et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J. 2014;35:2224–2231b.

    Article  PubMed  Google Scholar 

  19. Brandt MC, Reda S, Mahfoud F, Lenski M, Bohm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60:1956–65.

    Article  PubMed  Google Scholar 

  20. Ott C, Janka R, Schmid A, Titze S, Ditting T, Sobotka PA, et al. Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol CJASN. 2013;8:1195–201.

    Article  Google Scholar 

  21. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419–24.

    Article  CAS  PubMed  Google Scholar 

  22. Ott C, Mahfoud F, Schmid A, Ditting T, Veelken R, Ewen S, et al. Improvement of albuminuria after renal denervation. Int J Cardiol. 2014;173:311–5.

    Article  PubMed  Google Scholar 

  23. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60:1485–90.

    Article  CAS  PubMed  Google Scholar 

  24. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjonnaess E, Hjornholm U, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526–32.

    Article  CAS  PubMed  Google Scholar 

  25. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60:596–606.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Persu A, Azizi M, Burnier M, Staessen JA. Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension. 2013;62:450–2.

    Article  CAS  PubMed  Google Scholar 

  27. Kandzari DE, Bhatt DL, Sobotka PA, O’Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35:528–35.

    Article  PubMed  Google Scholar 

  28. Demaria AN. Reflections on renal denervation. J Am Coll Cardiol. 2014;63:1452–3.

    Article  PubMed  Google Scholar 

  29. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401. First study comparing renal denervation with a sham-control arm in patients with treatment resistant hypertension.

    Article  CAS  PubMed  Google Scholar 

  30. Bhatt DL, Bakris GL. Renal denervation for resistant hypertension. N Engl J Med. 2014;371:184.

    Article  PubMed  Google Scholar 

  31. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219–27. Post-hoc analyses of the Symplictiy HTN-3 trial revealing that methodolgical issues and poor performance and execution have hampered the results.

    Article  PubMed  Google Scholar 

  32. Schmieder RE. Renal denervation—a valid treatment option despite SYMPLICITY HTN-3. Nat Rev Cardiol. 2014;11:638.

    Article  PubMed  Google Scholar 

  33. Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J. 2013;34:2141–48, 2148b.

  34. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380:778.

    Article  PubMed  Google Scholar 

  35. Persu A, Sapoval M, Azizi M, Monge M, Danse E, Hammer F, et al. Renal artery stenosis following renal denervation: a matter of concern. J Hypertens. 2014;32:2101–5.

    Article  CAS  PubMed  Google Scholar 

  36. Bohm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65:766–74.

    Article  PubMed  Google Scholar 

  37. Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65:407–13.

    Article  CAS  PubMed  Google Scholar 

  38. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957-65. Study showing that renal denervation plus SSAHT decreases ambulatory blood pressure more than the same SSAHT alone.

  39. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol JASN. 2012;23:1250–7.

    Article  CAS  Google Scholar 

  40. Ott C, Mahfoud F, Schmid A, Toennes SW, Ewen S, Ditting T, et al. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. J Hypertens. 2015;33:1261–6. Pilot study in patients with chronic kidney disease indicating that renal denervation slows or even halts the decline of renal function.

    Article  CAS  PubMed  Google Scholar 

  41. Kim B-K, Boehm M, Mahfoud F, Mancia G, Park S, Hong M-K, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension in an Asian population: results from the global SYMPLICITY registry in South Korea (GSR KOREA) and comparison to Symplicity HTN-2. J Am Coll Cardiol. 2015;65(10_S). doi:10.1016/S0735-1097(15)61521-2.

  42. Davis MI, Filion KB, Zhang D, Eisenberg MJ, Afilalo J, Schiffrin EL, et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:231–41.

    Article  PubMed  Google Scholar 

  43. Pancholy SB, Shantha GP, Patel TM, Sobotka PA, Kandzari DE. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. Am J Cardiol. 2014;114:856–61.

    Article  PubMed  Google Scholar 

  44. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64:635–43. Autopsy study demonstrating the diverse distribution of efferent and afferent renal nerves along the renal arteries.

    Article  PubMed  Google Scholar 

  45. Tzafriri AR, Mahfoud F, Keating JH, Markham PM, Spognardi A, Wong G, et al. Innervation patterns may limit response to endovascular renal denervation. J Am Coll Cardiol. 2014;64:1079–87.

    Article  PubMed  Google Scholar 

  46. Vink EE, Goldschmeding R, Vink A, Weggemans C, Bleijs RL, Blankestijn PJ. Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc. 2014;29:1608–10.

    Google Scholar 

  47. Schmieder RE, Schmidt ST, Riemer T, Dechend R, Hagedorn I, Senges J, et al. Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. Hypertension. 2014;64:1067–72.

    Article  CAS  PubMed  Google Scholar 

  48. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226–32.

    Article  CAS  PubMed  Google Scholar 

  49. Patel HC, Hayward C, Ozdemir BA, Rosen SD, Krum H, Lyon AR, et al. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. Hypertension. 2015;65:401–6.

    Article  CAS  PubMed  Google Scholar 

  50. Fadl Elmula FE, Larstorp AC, Kjeldsen SE, Persu A, Jin Y, Staessen JA. Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension. Front Physiol. 2015;6:9.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, et al. Proceedings from the European Clinical Consensus Conference For Renal Denervation—considerations on future clinical trials design. Eur Heart J. 2015. Summary of the European Clinical Consensus Conference for renal denervation assessing the current gaps, unmet needs and future clinical trials design.

  52. Symplicity HTNI. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.

    Article  Google Scholar 

  53. Zuern CS, Eick C, Rizas KD, Bauer S, Langer H, Gawaz M, et al. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2013;62:2124–30.

    Article  PubMed  Google Scholar 

  54. Dorr O, Liebetrau C, Mollmann H, Gaede L, Troidl C, Rixe J, et al. Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension. 2014;63:984–90.

    Article  PubMed  Google Scholar 

  55. Wilder J. Basimetric approach (law of initial value) to biological rhythms. Ann N Y Acad Sci. 1962;98:1211–20.

    Article  CAS  PubMed  Google Scholar 

  56. Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54:3–10.

    Article  CAS  PubMed  Google Scholar 

  57. Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65:193–9. Study showing that BP reduction after RDN is less pronounced in patients with isolated systolic hypertension compared to combined hypertension.

    Article  CAS  PubMed  Google Scholar 

  58. Mahfoud F, Bakris G, Bhatt DL, Esler M, Kandzari D, Kario K, et al. Reduced blood pressure lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from pooled SYMPLICITY HTN trials. J Am Coll Cardiol. 2015;65(10_S). doi:10.1016/S0735-1097(15)61527-3.

  59. Ott C, Schmid A, Toennes SW, Ditting T, Veelken R, Uder M, et al. Central pulse pressure predicts BP reduction after renal denervation in patients with treatment resistant hypertension. EuroIntervention. 2015;11:110–6.

    Article  PubMed  Google Scholar 

  60. Esler M. Renal denervation for treatment of drug-resistant hypertension. Trends Cardiovasc Med. 2015;25:107–15.

    Article  PubMed  Google Scholar 

  61. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther. 2009;31:1116–23.

    Article  PubMed  Google Scholar 

  62. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880–6.

    Article  PubMed  Google Scholar 

  63. Desch S, Okon T, Heinemann D, Kulle K, Rohnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65:1202-8.

  64. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: renal denervation—an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837–41.

    Article  CAS  PubMed  Google Scholar 

  65. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2013;9 Suppl R:R58–66.

    Google Scholar 

  66. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149–57.

    Article  PubMed  Google Scholar 

  67. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Bohm M, Campese VM, et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031–45.

    Article  PubMed  Google Scholar 

  68. Walton T, Harding S, Rothman MT, Whitburn, RJ. Renal artery denervation with a new simultaneous multi-electrode catheter for treatment of resistant hypertension: 6-month results from the SYMPLICITY Spyral first-in-man study. EuroIntervention: J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2014. Euro14A-OP209.

  69. Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150–6.

    Article  PubMed Central  PubMed  Google Scholar 

  70. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132–40.

    Article  CAS  PubMed  Google Scholar 

  71. Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, et al. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol Off J Ger Cardiac Soc. 2014;103:117–24.

    Article  Google Scholar 

  72. Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, et al. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension. 2014;64:565–72.

    Article  CAS  PubMed  Google Scholar 

  73. Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, et al. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2015;10:1213–20.

    Google Scholar 

  74. Zeller T, Andersson B, Bohm M, Kuck KH, Sievert H, Graf T, et al. The paradise renal denervation system: initial clinical results from the achieve study. EuroIntervention: J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2014. 14A-OP205.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Christian Ott declares no conflict of interest. Roland E. Schmieder declares personal fees from Boston Scientific, Kona Medical, Medtronic, and Recor and grants from Rox Medical.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany

    Christian Ott & Roland E. Schmieder

Authors
  1. Christian Ott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland E. Schmieder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Ott.

Additional information

This article is part of the Topical Collection on Resistant Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ott, C., Schmieder, R.E. Renal Denervation for Resistant Hypertension: Past, Present, and Future. Curr Hypertens Rep 17, 65 (2015). https://doi.org/10.1007/s11906-015-0577-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-015-0577-6

Keywords

Search

Navigation